Ranibizumab News and Research

RSS
UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

UCSD molecular biologist to receive Breakthrough Prize in Life Sciences

AMD risk alleles fail to predict treatment response

AMD risk alleles fail to predict treatment response

Intravitreal ranibizumab shows little benefit after hemorrhage

Intravitreal ranibizumab shows little benefit after hemorrhage

Targeted deletion of major VEGF gene in mice induces vision loss

Targeted deletion of major VEGF gene in mice induces vision loss

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ranibizumab improves driving prospects for AMD patients

Ranibizumab improves driving prospects for AMD patients

Ranibizumab injections keep those with AMD driving longer

Ranibizumab injections keep those with AMD driving longer

Level of vision, not gain in letters seen, marks success of AMD treatment

Level of vision, not gain in letters seen, marks success of AMD treatment

Factors predictive of successful DME treatment revealed

Factors predictive of successful DME treatment revealed

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Nottingham researchers to lead Avastin clinical study for AMD

Nottingham researchers to lead Avastin clinical study for AMD

As needed ranibizumab effective for exudative AMD

As needed ranibizumab effective for exudative AMD

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Bevacizumab equivalent to ranibizumab in treating wet AMD

Bevacizumab equivalent to ranibizumab in treating wet AMD

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration